Carniques Celrá

Name

Carniques Celrá

Legal name

CÀRNIQUES CELRÀ S.L.

Website

https://ccelra.eu

Company type

Private

Founded year

2011

Operating status

Operating

Ownership category

akta.pro rank

Product category

Meat Processing

NAICS

Meat Processed from Carcasses (311612), Animal Slaughtering and Processing (3116), Rendering and Meat Byproduct Processing (311613)

SIC

Meat Packing Plants (2011), Food And Kindred Products (2000)

akta.pro primary industry

Pork Processing & Packing (AFAKALAB)

akta.pro secondary industries

Pork Fabrication & Primals Cutting (Carcass Breakdown) (AFANABAB), Pork Wholesale (Primal/Subprimal, Boxed Pork) (AFAIADAB)

Keywords

• Pork meat processing
• Meat export services
• Carcass cutting
• Pharmaceutical heparin production
• Animal by-product valorization

Headquarters

HQ city

Girona

HQ country

Spain

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Pork Meat Products: Production and sale of pork meat products including front part, middle part, hind part, trimming, offal, and bones. All animals result from genetic, nutritional, and market demand studies ensuring maximum homogeneity and healthiness.
2. By-product Valorization (Glicopepton): Transformation of pig mucosa into pharmaceutical products (heparin) and by-products into animal feed and organic fertilizers, creating additional revenue streams from waste valorization.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

Càrniques Celrà S.L. operates an industrial pork cutting and processing plant in Celrà (Girona, Spain), processing up to 5,200 pigs per day into organized product categories (front part, middle part, hind part, trimming, offal, bones) for export to international client companies. The company is also developing the Glicopepton Biotech project in partnership with Rovi and Costa Food Group to transform pig intestinal mucosa into pharmaceutical-grade heparin (LMWH), and participates in biofuel production from pork fat via a strategic alliance with Bioscor.

Product overview

Carniques Celrá operates as a meat processing company within the Olot Meats Group, offering pork carcass cutting and processing services with products organized into six main categories: Pork Front Part, Pork Middle Part, Pork Hind Part, Trimming, Offal, and Bones. The company also has a strategic biotech initiative called Glicopepton, developed in partnership with Rovi and Costa Food Group, which transforms pig mucosa into pharmaceutical-grade heparin. The product portfolio spans from raw pork products to high-value biotechnology applications, demonstrating full utilization of animal by-products through circular economy principles.

Differentiator

Problem solved

Functional benefit

Brands

• Glicopepton Biotech: A strategic biotechnology project born from collaboration between Càrniques Celrà, Costa Food Group, and Laboratorios Farmacéuticos Rovi, transforming pig intestinal mucosa into heparin and other high-value biotechnological products.

Products and services

• Pork Front Part Front portion pork cuts including shoulder, jowl, and shank products, processed and exported to international food distributors, retailers, and food service operators.
• Pork Middle Part Middle portion pork cuts from the central carcass section, processed and exported to international food distributors, retailers, and food service operators.
• Pork Hind Part Hind portion pork cuts from the rear carcass section, processed and exported to international food distributors, retailers, and food service operators.
• Trimming Pork trimming products intended for further processing, sold to international food industry customers.
• Offal Pork offal and organ meats for food and industrial applications, exported to international buyers.
• Bones Pork bones for food and industrial applications, exported to international buyers.
• Glicopepton Biotech (Pharmaceutical Heparin) Biotechnology project transforming pig intestinal mucosa into pharmaceutical-grade low molecular weight heparin (LMWH), an anticoagulant for preventing and treating human venous thromboembolic disease. Targeted at the pharmaceutical and healthcare industries, with by-products converted into animal feed and organic fertilizers.

Quantifiable outcome

• 30 Climate Credits obtained through PROMACC forest project equivalent to 3,000+ tons CO₂ fixation
• +1 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core and minor.

• BioscorcoreStrategic or Co-development Partner · 1 November 2025Strategic alliance for production of biofuels from pork fat. Bioscor is a leader in transforming organic waste into raw materials for biofuel production. Project produces SAF (Sustainable Aviation Fuel) component, minimizing environmental impact and contributing to circular economy.
• Consorci Forestal de Catalunya (CFC)minorStrategic or Co-development Partner · 1 January 2024Collaboration agreement for implementation of PROMACC forest project for climate change mitigation and adaptation. CFC brings majority of private forest owners in Catalonia.
• Fundació BoscosminorStrategic or Co-development Partner · 1 January 2024Partner in forest management collaboration agreement for sustainable forest management in Catalonia.
• Laboratorios Farmacéuticos RovicoreStrategic or Co-development Partner · 1 October 2022Strategic biotechnology partnership to develop Glicopepton Biotech project transforming pig mucosa into pharmaceutical-grade heparin (LMWH). Rovi contributes pharmaceutical industry expertise as leading Spanish pharmaceutical company. Joint investment of 40 million EUR in plant at Fraga Industrial Platform (Huesca), 25,000 m².
• Costa Food GroupcoreStrategic or Co-development Partner · 1 October 2022Third largest European pork producer contributing leadership in pork production and supply chain expertise. Partner in Glicopepton Biotech project alongside Rovi and Càrniques Celrà.

Scale indicators7 records

Recent moves10 records

Expansion highlights6 records

Broad incumbents

• JBS S.A. Global meat processing leader with significant pork operations across Brazil, the US, and Europe. Comparable in large-scale pork cutting and export, but with portfolio diversification across beef, poultry, and lamb.
• Smithfield Foods: World's largest pork processor and Hog Producer Europe subsidiary — operated as a US/global pork incumbent. Comparable in pork processing and export orientation but with broader geographic and product portfolio.
• Danish Crown: European pork cooperative giant (Denmark), one of the world's largest pork exporters. Operates globally across slaughtering, cutting, and processed meats with broader product portfolio and brand reach than Celrà.

Direct peers

• Costa Food Group: Spain's third-largest pork producer and Càrniques Celrà's joint-venture partner in the Glicopepton Biotech heparin project. Operates slaughtering, cutting, and cured-meat operations across Spain with significant export presence. Highly comparable in product mix, Spanish origin, and international export focus.
• Tönnies: Germany's largest pork slaughterer and processor, exporting globally. Closely comparable in pure-play pork processing, scale, and dependence on international wholesale distribution.
• Incarlopsa: Spanish pork producer headquartered in Cuenca with integrated slaughter, cutting, and cured-meat operations. Comparable mid-sized Iberian pork processor competing in similar European export markets.
• Grupo Fuertes / El Pozo: Spain's largest pork producer (El Pozo brand) with integrated slaughtering, cutting, and processed meats operations. One of Europe's largest pork exporters, directly comparable in B2B export channels, scale, and Spanish-origin sourcing model.
• Vall Companys: Vertically integrated Spanish pork producer with slaughtering, cutting, and processing operations. One of Spain's largest pork groups and a direct competitor in domestic and European wholesale channels.

Others

• Laboratorios Farmacéuticos Rovi: Spanish pharmaceutical company and Càrniques Celrà's JV partner in Glicopepton Biotech, contributing heparin manufacturing expertise. Comparable in the LMWH value chain but operates as a pharma partner rather than a competing meat processor.

Emerging players

• Bioscor: Strategic alliance partner of Olot Meats Group producing biofuels (including SAF) from organic waste including pork fat. A niche emerging player in waste-to-energy with direct technology overlap on Celrà's by-product valorization roadmap.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Carniques Celrá